What is MedVasc?
MedVasc is a medical technology company focused on revolutionizing varicose vein treatment. The company's core innovation, initially known as Solutio, aims to become the standard for administering anesthesia in this procedure. MedVasc's vision is to launch a market-leading product that enhances patient well-being, streamlines treatment, and provides procedural security for medical professionals. The company has successfully obtained a 200,000-euro grant from Vinnova, Sweden's innovation agency, further validating its technological advancements and market potential. MedVasc is committed to delivering the most efficient and safest treatment, prioritizing minimal pain and maximum patient comfort.
How much funding has MedVasc raised?
MedVasc has raised a total of $3.7M across 2 funding rounds:
Other Financing Round
$1M
Stock/Share Issuance
$2.7M
Other Financing Round (2025): $1M, investors not publicly disclosed
Stock/Share Issuance (2026): $2.7M, investors not publicly disclosed
What's next for MedVasc?
With the recent major strategic investment, MedVasc is poised for significant scaling and market penetration. The company's focus will likely shift towards accelerating the commercialization of its Solutio product, expanding its manufacturing capabilities, and broadening its market reach. Further strategic partnerships and continued research and development may also be on the horizon as MedVasc aims to establish its innovative solution as the industry standard for varicose vein anesthesia administration. The company's trajectory suggests a move towards later-stage growth and market adoption.
See full MedVasc company page
